or Try an Advanced Search...

    Technical Analysis for AVTE - Aerovate Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 21.04 2.94% 0.60
    AVTE closed up 2.94 percent on Wednesday, May 8, 2024, on 87 percent of normal volume.
    Earnings due: May 13
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical AVTE trend table...
    Date Alert Name Type % Chg
    Multiple of Ten Bullish Other 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Multiple of Ten Bullish Other 2.94%
    Wide Bands Range Expansion 2.94%
    Oversold Stochastic Weakness 2.94%
    NR7 Range Contraction 2.04%
    Narrow Range Bar Range Contraction 2.04%
    Inside Day Range Contraction 2.04%
    Wide Bands Range Expansion 2.04%
    Older End-of-Day Signals for AVTE ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 10 hours ago
    Rose Above 10 DMA about 10 hours ago
    Up 2% about 10 hours ago
    10 DMA Resistance about 11 hours ago
    Possible Inside Day about 12 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AVTE Chart by TradingView
    Basic chart:

    Profile

    Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Chemical Compounds Hypertension Orphan Drug Pulmonary Arterial Hypertension Pulmonary Hypertension Imatinib Piperazines

    Is AVTE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 4 Aerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares
    Mar 27 Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
    Mar 27 Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023
    Mar 25 Aerovate Therapeutics reports FY results
    Mar 25 Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
    Mar 21 Chief Medical Officer Hunter Gillies Sells 7,000 Shares of Aerovate Therapeutics Inc (AVTE)
    Mar 21 Insider Sell: Aerovate Therapeutics Inc's (AVTE) Chief Technical Officer Marinus Verwijs Sells ...
    Mar 6 Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
    Dec 29 Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth
    Dec 16 Insider Sell Alert: Chief Medical Officer Hunter Gillies Sells 12,000 Shares of Aerovate ...
    See more AVTE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 32.415
    52 Week Low 9.41
    Average Volume 158,129
    200-Day Moving Average 18.15
    50-Day Moving Average 24.48
    20-Day Moving Average 22.08
    10-Day Moving Average 20.79
    Average True Range 1.78
    RSI (14) 42.20
    ADX 18.53
    +DI 18.64
    -DI 20.51
    Chandelier Exit (Long, 3 ATRs) 23.35
    Chandelier Exit (Short, 3 ATRs) 25.00
    Upper Bollinger Bands 25.76
    Lower Bollinger Band 18.40
    Percent B (%b) 0.36
    BandWidth 33.34
    MACD Line -1.25
    MACD Signal Line -1.19
    MACD Histogram -0.066
    Fundamentals Value
    Market Cap 582.15 Million
    Num Shares 27.7 Million
    EPS -2.74
    Price-to-Earnings (P/E) Ratio -7.68
    Price-to-Sales 0.00
    Price-to-Book 4.52
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 23.13
    Resistance 3 (R3) 22.95 22.07 22.78
    Resistance 2 (R2) 22.07 21.54 22.16 22.66
    Resistance 1 (R1) 21.56 21.21 21.82 21.74 22.55
    Pivot Point 20.68 20.68 20.81 20.77 20.68
    Support 1 (S1) 20.17 20.15 20.43 20.35 19.53
    Support 2 (S2) 19.29 19.82 19.38 19.42
    Support 3 (S3) 18.78 19.29 19.30
    Support 4 (S4) 18.96